Dr Agarwals Healthcare IPO began on – Jan 29, 2025. It will close on – Jan 31, 2025. The Total IPO Size is ₹3,027.26 Crore Approx. The company set its IPO price is ₹382 to ₹402 per share Per Share. There are three basic categories in Dr Agarwals Healthcare IPO Subscription:- 1) Qualified Institutional Buyers.  2) Non-Institutional Investors.  3) Retail.

Incorporated in 2010, Dr. Agarwal’s Health Care Limited offers a comprehensive range of eye care services, including cataract and refractive surgeries, consultations, diagnoses, non-surgical treatments, and the sale of optical products, contact lenses, accessories, and eye care-related pharmaceutical items.

The Services provided by the company are:-

Cataract surgeries Offer cataract surgical treatments at its Facilities, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery and glued intraocular lens treatments;

Refractive surgeries: Refractive surgeries are procedures that correct eye refractive errors, helping individuals reduce or eliminate their need for glasses and contact lenses. The main types include LASIK, SMILE, implantable collamer lenses, and photorefractive keratectomy (PRK).

Other surgeries: Offer a range of other surgical treatments for eye ailments, such as surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty and surgeries for the treatment of glaucoma and pterygium.

As of September 30, 2024, the company’s Indian network has 28 hubs (Tertiary Facilities, including three COEs) and 165 spokes (53 Primary and 112 Secondary Facilities).

As of September 30, 2024, there were 737 doctors providing care to patients across the company’s facilities. During this period, the company served 2.13 million patients and performed 220,523 surgeries. In the six months leading up to September 30, 2024, they served 1.15 million patients and conducted 140,787 surgeries.

Competitive Strength

• Largest eye care services provider in India with a trusted brand
• End-to-end, comprehensive eye care services offering
• Scalable, asset-light, hub-and-spoke operating model
• Proven clinical excellence is driven by a strong clinical board and a history of surgical innovations.
• Doctor-promoters leading a team of qualified medical professionals and supported by experienced management
• Proven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability

As of September 30, 2024, the company has a presence in India across 117 metro and non-metro cities spanning 14 states and four union territories through 193 Facilities.